Zevra Therapeutics, Inc. has seen a notable change in its stock ownership structure, as reported in a recent filing. FMR LLC, an investment management firm, now holds 9.4% of the company’s common stock. This development is significant as it signals increased investor confidence in Zevra and its future prospects.

Founded in 2008, Zevra Therapeutics, Inc. operates in the pharmaceutical preparations industry, specifically focusing on developing innovative therapies. The company is publicly traded on the Nasdaq under the ticker symbol ZVRA. Its business address is located at 101 Federal Street, Boston, MA. Zevra was previously known as KemPharm, Inc., reflecting its evolution in the pharmaceutical landscape.

The recent filing, submitted on November 5, 2026, indicates that FMR LLC beneficially owns 5,562,780.78 shares of Zevra’s common stock. This ownership gives FMR LLC sole voting power over 5,548,994 shares and sole dispositive power over the entire amount. Abigail P. Johnson, the Chairman and CEO of FMR LLC, is also noted as a significant figure in this filing.

The filing highlights that FMR LLC and its affiliates, collectively referred to as the “FMR Reporters,” are now positioned as key stakeholders in Zevra. The filing also notes that Fidelity Contrafund, a mutual fund managed by Fidelity, holds approximately 5.6% of Zevra’s total outstanding common stock. This shows a strategic alignment among investment entities interested in Zevra’s growth.

This increase in ownership by FMR LLC may have various implications for Zevra and its stakeholders. Current investors and market analysts will likely keep a close eye on how this change might affect the company’s strategic direction and operational decisions. Additionally, other players in the pharmaceutical preparations sector may need to consider the competitive landscape as FMR LLC’s influence grows.

Looking ahead, the filing does not specify what actions will follow this significant ownership change. However, it is clear that FMR LLC's involvement could lead to increased scrutiny of Zevra’s business strategies and potential collaborations in the future.